Pharmaceuticals & Biopharmaceuticals

Cambridge, Mass. – November 05, 2026 -- Harbour BioMed (HKEX: 02142) has appointed Vivian Feng, a business development executive with over 16 years of biotech and pharma experience who most recently led BD at Fosun Pharma, as Senior Vice President, Head of External Collaboration. Feng will be based in Shanghai and report directly to Chief Strategy Officer Mike Patten.

Feng will oversee business development and licensing across the HBM Group

Feng will lead the antibody developer's external collaboration strategy, linking its platform, pipeline and innovation capabilities with outside partners. She will also foster synergy and information flow across HBM Group entities and its NewCos.

Her mandate includes building the processes and team capabilities for a scalable, risk-controlled external collaboration function.

Bridgewater – November 04, 2026 -- Insmed Incorporated (Nasdaq: INSM) will put management in front of investors at two healthcare conferences within a span of 15 days, starting November 16 in London.

Insmed management to present at Jefferies in London on November 16

The company will appear at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 9:00 a.m. ET.

Evercore session in Coral Gables is set for December 1

Management will then present at the Evercore 9th Annual Healthcare Conference in Coral Gables, Florida, on Tuesday, December 1, 2026, at 9:10 a.m. ET.

Both presentations will be webcast live and archived for 30 days

Both events will be webcast live through the investor relations section of Insmed's website. Each webcast will remain archived for 30 days after the live event ends.

BOSTON – November 04, 2026 -- Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index and placed in the top three in all three categories: research, clinical development and commercial. The rankings, developed with IDEA Pharma, a division of SAI MedPartners, were revealed on the CNS Summit 2026 main stage at Encore Boston Harbor.

Index ranks 30 pharma companies on public digital initiatives and investments

Now in its 11th year, the Index scores the top 30 pharmaceutical companies on digital innovation. It draws only on publicly reported initiatives and investments from July 2025 through July 2026.

The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA.

Roche, Novo Nordisk and Recursion lead individual categories

Roche led the commercial category and Novo Nordisk led clinical development. Recursion led research.

Brussels – November 04, 2026 -- The head of Germany's pharmaceutical industry association BPI has said the EU is not prepared for a health crisis, calling European and national policy inadequate for the current geopolitical tensions.

BPI Chairman Oliver Kirst made the remarks at the association's autumn reception at the Bibliothèque Solvay in Brussels. He described the lack of crisis resilience as irresponsible and said EU action is too slow and too bureaucratic.

Critical Medicines Act still awaits formal adoption

Kirst named the Critical Medicines Act (CMA) as the prime example of EU hesitation. He called its aim of returning critical medicine production to Europe right and urgent. The act, he noted, has been debated for a long time and still has to be formally adopted.

Chairman lists open questions on production, storage and protection

Kirst said too many questions remain unanswered:

TORONTO – November 03, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) has entered into an at-the-market program that lets it sell up to US$75 million of common shares through Jefferies LLC to fund late-stage cardiac drug development.

Cardiol restricts ATM share sales to U.S. trading venues

Shares will be sold in ordinary brokers' transactions on the Nasdaq Capital Market or other U.S. trading markets at prevailing market prices. No shares will be sold through the Toronto Stock Exchange or elsewhere in Canada.

Sales will proceed under a prospectus supplement dated November 3, 2026. The supplement attaches to Cardiol's Canadian and U.S. base shelf prospectuses, both dated September 15, 2026. The U.S. base prospectus forms part of a Form F-10 registration statement that became effective on September 16, 2026.

Philadelphia – November 03, 2026 -- Verismo Therapeutics' SynKIR-110 achieved the fastest tumor control among three CAR T designs in preclinical mesothelioma models while producing roughly 10-fold less IFNγ and 30-fold less TNFα and IL-2 than a CD28-based single-chain CAR T.

The company will present the data at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting in Phoenix (Abstract 253). The study compared SynKIR-110 with CD28- and 4-1BB-based single-chain CAR T cells in mesothelioma xenograft models.

SynKIR-110 shows lower exhaustion markers than both single-chain comparators

Tumor-infiltrating SynKIR-110 CD8 T cells expressed fewer of the exhaustion markers TIM3, LAG3 and PD1 than cells from either single-chain design. In vitro data also showed reductions in T cell exhaustion, off-target proliferation and toxicity.

Shanghai – November 03, 2026 -- IASO Bio's FUCASO, the first BCMA-targeted CAR-T therapy approved in Singapore, will be covered under the country's Cancer Drug List (CDL) from December 1, 2026. The coverage follows the product's commercial launch in Singapore on November 3 with local partner Pills and Pokes.

Singapore's HSA approved FUCASO in June 2026 for late-line multiple myeloma

The Health Sciences Authority cleared FUCASO for adults with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least three prior lines of therapy. Those lines must include at least one proteasome inhibitor and one immunomodulatory agent. IASO Bio describes the product as the world's first fully human BCMA-targeted CAR-T therapy.

HANGZHOU – November 04, 2026 -- Minghui Pharmaceutical will receive an upfront payment of USD 110 million from ASKA Pharmaceutical under an exclusive license for MHB018A in Japan, with up to USD 330 million in further milestone payments on offer.

MHB018A is a subcutaneously administered antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for thyroid eye disease (TED). ASKA gains exclusive rights to develop, seek regulatory approval for and commercialize the drug in Japan. Minghui keeps all rights outside Japan and continues to lead global development.

Deal combines USD 440 million in headline value with royalties up to mid-30%

Minghui is eligible for development, regulatory and commercial milestones totaling up to USD 330 million, on top of the USD 110 million upfront. It will also receive tiered royalties of up to mid-30% on net sales in Japan.

Incheon – November 03, 2026 -- Samsung Biologics (KRX: 207940.KS) has earned an ESG Risk Rating score of 9.0 from Morningstar Sustainalytics, placing the contract development and manufacturing organization (CDMO) among the top 0.5% of companies assessed in the pharmaceuticals industry.

Samsung Biologics moves from 'Low Risk' to the lowest of five risk categories

The company advanced to 'Negligible Risk' from its previous 'Low Risk' rating. Under Sustainalytics' methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, and lower scores reflect lower overall risk.

Morningstar Sustainalytics, an independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide. It measures their exposure to material ESG risks and how effectively those risks are managed.

SUZHOU – November 03, 2026 -- CStone Pharmaceuticals (HKEX: 2616) will lead Phase I development of Kimia Therapeutics' potential first-in-class DNA damage response (DDR) cancer drug in mainland China and Australia, while Kimia reimburses the applicable clinical development costs.

CStone gains milestone and royalty rights without funding the trials

Under the clinical collaboration agreement, CStone is eligible for milestone payments and royalties on global net sales of the asset during the applicable royalty term. Kimia will supply the clinical drug, scientific guidance and product-related regulatory oversight. The announcement did not disclose payment amounts or royalty rates.

The asset targets the DDR pathway, which solid tumor cells rely on to survive.